BerGenBio

Report Publication Announcement • Nov 4, 2021

BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST

BERGENBIO ASA: INVITATION TO THIRD QUARTER 2021 RESULTS PRESENTATION AND WEBCAST

Bergen, Norway, 4 November 2021?- BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical need, will be announcing its results for the third quarter

2021 on Tuesday 16 November 2021. The briefing will take place at 10:00 am CET

at:

Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslo

where BerGenBio's senior management team will provide an update on the Company

followed by a Q&A session. To attend in person please register by mail to

hanna.haug@carnegie.no

The presentation will webcast live and a link will be available at

www.bergenbio.com in the Investors/Financial Reports section. A recording will

be available shortly after the webcast has finished.

The third quarter report and presentation will be available on the Company's

website in the Investors/Financial Reports section from 7:00 am CET the same

day.

-Ends-

Contacts

Martin Olin

Chief Executive Officer, BerGenBio ASA

ir@bergenbio.com

Rune Skeie

Chief Financial Officer, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing. In parallel, BerGenBio is

developing companion diagnostic test to identify patient populations most likely

to benefit from AXL inhibition. This is expected to facilitate more efficient

registration trials supporting a precision medicine-based commercialisation

strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.